https://www.merckgroup.com/en/company/who-we-are/healthcare.html

With a holistic approach, we design and develop medicines and intelligent devices that provide ongoing care for patients beyond their treatment. This includes new medications to treat conditions such as cancer or multiple sclerosis (MS), but also innovative technologies that make life easier for patients. For example, our injection device and disease monitoring software allow patients with MS to self-inject their medicine and monitor its administration. With cancer, our precise approach uses biomarkers that can match potential treatment to individual patients.

Our goal is to support people at every stage of life – also when it comes to helping create new life. We have helped many women and couples achieve their dream of having a baby. As the global market leader in fertility treatments, we do what we do with passion – and we think further ahead. We have complemented our portfolio by fertility technologies, aiming to further increase the possibility of in vitro fertilization (IVF) success.

These are our therapeutic areas:

• Oncology

Our drug is a standard treatment in colorectal cancer as well as carcinoma of the head and neck. Building on new discoveries made by our research team, we are also doing innovative work in the field of immuno-oncology.

• Neurodegenerative Diseases

We help to treat relapsing forms of multiple sclerosis (MS), one of the most common neurological diseases among young adults. Currently we are also developing new medications in an effort to make life easier for MS patients.
• General Medicine
We offer medications for the treatment of type 2 diabetes, cardiovascular and thyroid diseases. Each year, about 59 million patients are treated with our drugs in these therapeutic areas.

•  Endocrinology

We aim to help children and adults with growth hormone deficiencies.

•  Fertility

Our goal is to provide healthcare professionals and patients with a variety of innovative treatment options and devices as well as advanced fertility technologies.